Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
SFN 2025 | San Diego, CA
Nov 15 - 19, 2025
Poster
ARV-102, a PROTAC LRRK2 Degrader, Modulates Pathways Associated With Parkinson’s Disease and Progressive Supranuclear Palsy: Proteomic Analyses of CSF From Non-human Primates and Healthy VolunteersISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast CancerISPOR-EU 2025 | Glasgow, UK
Nov 9 - 12, 2025
Poster
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility DataSITC 2025 | National Harbor, MD
Nov 5 - 9, 2025
Poster
Preclinical Antitumor Activity of Potent and Orally Bioavailable PROTAC HPK1 Degraders as Monotherapy or Combined With an Anti-PD-1 AntibodyAACR-NCI-EORTC 2025 | Boston, MA
Oct 22 - 26, 2025
Poster
Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer ModelsAACR-NCI-EORTC 2025 | Boston, MA
Oct 22 - 26, 2025
Poster
Preclinical Activity of ARV-806, a PROTAC KRAS G12D DegraderESMO 2025 | Berlin, Germany
Oct 17 - 21, 2025
Presentation
TACTIVE-N: Phase 2 Study of Neoadjuvant Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, or Anastrozole in Postmenopausal ER+/Human Epidermal Growth Factor Receptor 2-Negative Localized Breast CancerESMO 2025 | Berlin, Germany
Oct 17 - 21, 2025
Presentation
Patient-Reported Outcomes (PROs) with Vepdegestrant (VEP) vs Fulvestrant (FUL) in Patients (pts) with Estrogen Receptor (ER) 1 Gene Mutated (ESR1m) ER+/Human Epidermal Growth Factor Receptor 2 (HER2): Advanced Breast Cancer (aBC) in the Phase 3 VERITAC-2 TrialWMS 2025 | Vienna, Austria
Oct 7 - 11, 2025